Bolt Biotherapeutics Q3 FY23: revenue $2.5M; diluted EPS −$8.60

Key figures from this report

These are the numbers Bolt Biotherapeutics reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$2.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
2. Net income−$16.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
3. Diluted EPS−$8.60No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.4310-Q income statement, on EDGAR
4. Cash and cash equivalents$9.2MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations−$16.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables